News

Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about its single commercialized drug that day. As a result, its shares were trading more than 6% higher in late-session trading on the stock market, eclipsing the basically flatlining S&P 500 index.

A victory for Vazkepa

Amarin announced that morning, no doubt with great satisfaction, that its cardiovascular drug Vazkepa (branded as Vascepa in the U.S. market) has received an extension to its patent exclusivity in the European Union (E.U.), thanks to a new patent covering the drug. The 27-country bloc's European Patent Office (EPO) tacked on eight years to Vazkepa's term, so it will now expire in April 2039.

Patent exclusivity is crucial for pharmaceutical companies, as they have far more scope to set the price for their drugs when there is no competition.

Since Vazkepa/Vascepa is so crucial for Amarin's success, the company has been vigorously defending the intellectual property foundational to the drug. It said it recently notched a victory in a dispute over a separate patent for the drug that was adjudicated by the EPO.

In the press release trumpeting the extension, Amarin quoted CEO Patrick Holt as saying the decision "enhances the potential impact that this product can have for patients and the growth potential for Vazkepa across the continent."

Amarin hasn't always won

Amarin hasn't always been successful in the regulatory sphere with its solitary product. It fought like a tiger to fend off challenges to Vascepa's exclusivity on the U.S. market, and ultimately lost in a 2020 court decision. So the victory in Europe is particularly meaningful.

Having said that, though, the company is very much a one-trick pony with Vazkepa/Vascepa.

Should you invest $1,000 in Amarin Plc right now?

Before you buy stock in Amarin Plc, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amarin Plc wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

*Stock Advisor returns as of April 1, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.